Table 4. Patients' characteristics.
| Early disease (45 TNBC patients) | Early disease (21HR-positive) | Metastatic TNBC patients (10 Patients) | |||
|---|---|---|---|---|---|
| Age | Age | Age | |||
| Median, range | 53 (35-77) | Median, range | 57 (37-84) | Median, range | 66 (45-82) |
| N | N | N | |||
| Menopausal status | Menopausal status | Menopausal status | |||
| Premenopausal | 11 (24.4%) | Premenopausal | 5 (23.8%) | Premenopausal | 2(20%) |
| Postmenopausal | 28(62.2%) | Postmenopausal | 12(57.1%) | Postmenopausal | 7(70%) |
| Unknown | 6(13.3%) | Unknown | 4(19%) | Unknown | 1(10%) |
| Tumor size | Tumor size | Disease sites | |||
| pT1 | 15(33.3%) | pT1 | 2(9.5%) | 1 | 6(60%) |
| pT2 | 19(42.2%) | pT2 | 6(28.6%) | 2 | 1(10%) |
| pT3 | 1(2.2%) | pT3 | 6(28.6%) | 3 | 1(10%) |
| Unknown | 10(22%) | Unknown | 8(38%) | ≥4 | 1(10%) |
| Unknown | 1(10%) | ||||
| Lymph node status | Lymph node status | Predominantly visceral disease | |||
| Node-negative | 23(51.1%) | Node-negative | 3 (14.3%) | Yes | 2 (20%) |
| Node-positive | 12(26.7%) | Node-positive | 12(57.1%) | No | 8(80%) |
| Unknown | 10(22%) | Unknown | 6(28.6%) | Unknown | 0(0%) |
| Histologic grade | Histologic grade | Primary breast cancer | |||
| Grade 1 | 1(2.2%) | Grade 1 | 0(0%) | Adjuvant | 3(30%) |
| Grade 2 | 8(17.8%) | Grade 2 | 6(28.6%) | Metastatic | 6(60%) |
| Grade 3 | 27(60%) | Grade 3 | 9(42.9%) | Unknown | 1(10%) |
| Grade 4 | 2(4.4%) | Grade 4 | 1(4.8%) | ||
| Unknown | 7(15.5%) | Unknown | 5(23.8%) | ||
| ER/PR tumor status | ER/PR tumor status | ER/PR tumor status | |||
| Positive | 0(0%) | Positive | 21(100%) | Positive | 0(0%) |
| Negative | 45(100%) | Negative | 0(0%) | Negative | 10(100%) |
| Unknown | 0 (0%) | Unknown | 0 (0%) | Unknown | 0 (0%) |
| HER2 tumor status | HER2 tumor status | HER2 tumor status | |||
| Positive* | 0(0%) | Positive* | 0(0%) | Positive* | 0(0%) |
| Negative | 45(100%) | Negative | 21(100%) | Negative | 10(100%) |
| Unknown | 0(0%) | Unknown | 0(0%) | Unknown | 0(0%) |